Hosted on MSN1mon
GeneDx targeted in short report by Grizzly Research
GeneDx, which was previously known as Sema4, is now valued at $2 billion on the stock exchange, almost seven times its selling price, just 1.5 years after the sale.
Forbes5d
GeneDx Holdings
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and ...
Business Insider1mon
GeneDx price target raised to $115 from $95 at BTIG
BTIG raised the firm’s price target on GeneDx (WGS) to $115 from $95 and keeps a Buy rating on the shares. The shares are up roughly 40% after a “strong” Q4, as revenue beat by 16% ...
Nasdaq13d
Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies
GeneDx recognized for its innovative approach to accelerating genetic diagnosis and transforming the future of healthcare by ending the diagnostic odyssey “Our list of the Most Innovative ...
Seeking Alpha3d
WGS GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well ...
MarketWatch1mon
GeneDx Shares Surge on 4Q Revenue Growth
Shares of GeneDx Holdings shot up 24% following higher-than-expected revenue in its fourth quarter. Shares were trading around $95. Over the last year, the stock is up nearly 1800%. The patient ...
Hosted on MSN1mon
BTIG maintains GeneDx stock Buy rating, $95 target amid fraud claim
O n Wednesday, BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ...
Business Wire18d
GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision ...
Business Insider1mon
GeneDx reports FY24 EPS ($1.94) vs. ($7.23) last year
Reports FY24 revenue $305.5M, consensus $290.82M .”The fourth quarter capped an outstanding year for GeneDx (WGS), as we work to end the diagnostic odyssey with earlier intervention using our ...
ETF Daily News3d
GeneDx Holdings Corp. (NASDAQ:WGSWW) Short Interest Down 47.6% in March
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever GeneDx Holdings Corp., through its subsidiaries, provides genomics-related ...
Yahoo Finance27d
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
GAITHERSBURG, Md., March 04, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its ...
Yahoo Finance10d
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., March 20, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of March 15 ...